Saxagliptin 5mg Tablets Recalled for Manufacturing Practice Deviations
Glenmark Pharmaceuticals is voluntarily recalling Saxagliptin 5mg tablets nationwide due to CGMP deviations. Affected lot numbers are 17232460 and 17241194.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: This is a voluntary Class II recall with no reported illnesses, injuries, or deaths. The source describes CGMP deviations without detailing a specific acute safety hazard, and the recall is classified as voluntary precautionary in nature.
Plain-English summary
Glenmark Pharmaceuticals Inc., USA is voluntarily recalling Saxagliptin 5mg tablets distributed nationwide. The recall affects 30-count bottles (NDC# 68462-727-30) and 90-count bottles (NDC# 68462-727-90). Affected lot numbers are 17232460 (expiration November 2025) and 17241194 (expiration June 2026).
The FDA classified this as a Class II recall due to CGMP (Current Good Manufacturing Practice) deviations identified at the manufacturing facility. The recall was initiated by Glenmark on March 13, 2025.
Patients currently taking Saxagliptin from the affected lot numbers should consult their healthcare provider or pharmacist. Do not stop taking your medication without consulting your doctor, as Saxagliptin is used to treat type 2 diabetes, and stopping abruptly could affect blood sugar control.
The recalled product
- Product
- SAXAGLIPTIN (SAXAGLIPTIN)
- Brand
- SAXAGLIPTIN
- Manufacturer
- Glenmark Pharmaceuticals Inc., USA
- Category
- Drug — Diabetes medication
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (5)
- Lot # 17232460
- exp. date Nov-25 17232460
- exp. date Nov-25 17241194
- exp. date Jun-26 17241194
- exp. date Jun-26
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 39 recalled by Glenmark Pharmaceuticals Inc., USA under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 39 products in this recall →Related recalls
Same brand · SAXAGLIPTIN
- ModerateFDA Recalls Saxagliptin Tablets Due to Manufacturing Deviations
FDA (Drugs) · 2025-04-16
Same manufacturer · Glenmark Pharmaceuticals Inc., USA
See all →- ModerateAzelaic Acid Gel 15% Recalled Over Grainy, Gritty, or Sandy Texture
FDA (Drugs) · 2026-08-05
- ModerateAlyacen 7/7/7 birth control tablets failed total impurities specification
FDA (Drugs) · 2026-06-24
- ModerateOndansetron tablets recalled because blister packs are not fully sealed
FDA (Drugs) · 2026-01-07
- CriticalFrozen chopped methi recalled after testing positive for Salmonella
FDA (Drugs) · 2025-12-17
- ModerateBisoprolol and hydrochlorothiazide tablets recalled over traces of another drug
FDA (Drugs) · 2025-12-10
Same hazard · manufacturing deviation
See all →- ModerateSynjardy XR Tablets Recalled Due to Manufacturing Deviations
FDA (Drugs) · 2026-07-08
- ModerateDuloxetine delayed-release capsules recalled for N-nitroso impurity contamination
FDA (Drugs) · 2026-05-13
- ModerateFentanyl Citrate Injectable Solution Recalled for cGMP Deviations
FDA (Drugs) · 2026-05-06
- ModerateiVIZIA Dry Eye Lubricant Drops Recalled for Sterility Assurance
FDA (Drugs) · 2026-05-06
- ModerateFurosemide tablets recalled for presence of N-nitroso impurity
FDA (Drugs) · 2026-04-29